Prognostic biomarkers in HCV cirrhosis

In 2015, in close collaboration with HCV Research UK, STOP-HCV established the STOP-HCV Cirrhosis Study - a longitudinal study of patients with severe liver disease.

MRI liver

The cohort consists of 1264 patients recruited from 31 hospital sites across the UK. Each year data and samples are collected from these patients with the aim of identifying biomarkers which identify those patients most at risk of liver disease progression and/or development of liver cancer.